基线LDL-C水平与LDL-C降低后全因及心血管死亡风险的关联:系统评价与Meta分析
该系统评价与Meta分析检索至2018年2月2日的随机临床试验,纳入34项他汀、依折麦布及PCSK9抑制性单克隆抗体试验,比较更强化与更不强化降LDL-C治疗。更强化治疗组全因死亡率7.08% vs 更不强化组7.70%(RR 0.92,95%CI 0.88–0.96),心血管死亡率3.48% vs 4.07%(RR 0.84,95%CI 0.79–0.89)。Meta回归显示基线LDL-C每升高40 mg/dL,全因死亡RR变化0.91(95%CI 0.86–0.96,P=.001),心血管死亡RR变化0.86(95%CI 0.80–0.94,P<.001);但仅在基线LDL-C≥100 mg/dL时Meta分析交互作用显著(P<.001)。基线LDL-C≥160 mg/dL的试验全因死亡降低最明显(RR 0.72,95%CI 0.62–0.84,每1000人年减少4.3例死亡)。
要点
- 更强化 vs 更不强化降LDL-C:全因死亡率7.08% vs 7.70%(RR 0.92,95%CI 0.88–0.96)。
- 更强化 vs 更不强化降LDL-C:心血管死亡率3.48% vs 4.07%(RR 0.84,95%CI 0.79–0.89)。
- 基线LDL-C每升高40 mg/dL,全因死亡RR变化0.91(95%CI 0.86–0.96,P=.001),心血管死亡RR变化0.86(95%CI 0.80–0.94,P<.001)。
- Meta分析中仅基线LDL-C≥100 mg/dL时更强化治疗的死亡获益交互作用显著(P<.001);<100 mg/dL时该关联不存在。
- 基线LDL-C≥160 mg/dL的试验全因死亡降低最明显(RR 0.72,95%CI 0.62–0.84,每1000人年减少4.3例死亡)。
适用人群与场景
- 纳入34项随机临床试验,比较更强化与更不强化(较弱药物、安慰剂或对照)降LDL-C治疗的患者,干预药物为他汀、依折麦布或PCSK9抑制性单克隆抗体。
- 更强化治疗组136 299例,更不强化组133 989例。
诊断标准与关键阈值
- 基线LDL-C分层阈值:100 mg/dL(Meta分析交互作用P<.001)及160 mg/dL(全因死亡降低最明显)。
研究设计与关键结果
- 系统评价与Meta分析,34项随机临床试验,更强化组136 299例 vs 更不强化组133 989例;主要终点为全因死亡和心血管死亡。
- 全因死亡率更强化组7.08% vs 更不强化组7.70%(RR 0.92,95%CI 0.88–0.96)。
- 心血管死亡率更强化组3.48% vs 更不强化组4.07%(RR 0.84,95%CI 0.79–0.89)。
- Meta回归:基线LDL-C每升高40 mg/dL,全因死亡RR变化0.91(95%CI 0.86–0.96,P=.001;绝对风险差−1.05例/1000人年,95%CI −1.59至−0.51)。
- Meta回归:基线LDL-C每升高40 mg/dL,心血管死亡RR变化0.86(95%CI 0.80–0.94,P<.001;绝对风险差−1.0例/1000人年,95%CI −1.51至−0.45)。
- Meta分析中仅基线LDL-C≥100 mg/dL时更强化治疗与死亡降低的交互作用显著(P<.001);基线LDL-C<100 mg/dL时该关联不存在。
- 基线LDL-C≥160 mg/dL的试验全因死亡降低最明显(RR 0.72,95%CI 0.62–0.84,P<.001;每1000人年减少4.3例死亡)。
- 更强化降LDL-C对心肌梗死、血运重建和MACE的风险降低也随基线LDL-C升高而逐渐增大。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析(含Meta回归),纳入34项随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基线LDL-C水平较高(≥100 mg/dL)的患者从降LDL-C治疗中可能获益最大;基线LDL-C<100 mg/dL时更强化治疗的死亡获益关联不存在。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Effects on specific fatal and nonfatal end points appear to vary for low-density lipoprotein cholesterol (LDL-C)-lowering drug trials.
OBJECTIVE: To evaluate whether baseline LDL-C level is associated with total and cardiovascular mortality risk reductions.
DATA SOURCESAND STUDY SELECTION: Electronic databases (Cochrane, MEDLINE, EMBASE, TCTMD, ClinicalTrials.gov, major congress proceedings) were searched through February 2, 2018, to identify randomized clinical trials of statins, ezetimibe, and PCSK9-inhibiting monoclonal antibodies.
DATA EXTRACTION AND SYNTHESIS: Two investigators abstracted data and appraised risks of bias. Intervention groups were categorized as "more intensive" (more potent pharmacologic intervention) or "less intensive" (less potent, placebo, or control group).
MAIN OUTCOMES AND MEASURES: The coprimary end points were total mortality and cardiovascular mortality. Random-effects meta-regression and meta-analyses evaluated associations between baseline LDL-C level and reductions in mortality end points and secondary end points including major adverse cardiac events (MACE).
RESULTS: In 34 trials, 136 299 patients received more intensive and 133 989 received less intensive LDL-C lowering. All-cause mortality was lower for more vs less intensive therapy (7.08% vs 7.70%; rate ratio [RR], 0.92 [95% CI, 0.88 to 0.96]), but varied by baseline LDL-C level. Meta-regression showed more intensive LDL-C lowering was associated with greater reductions in all-cause mortality with higher baseline LDL-C levels (change in RRs per 40-mg/dL increase in baseline LDL-C, 0.91 [95% CI, 0.86 to 0.96]; P = .001; absolute risk difference [ARD], -1.05 incident cases per 1000 person-years [95% CI, -1.59 to -0.51]), but only when baseline LDL-C levels were 100 mg/dL or greater (P < .001 for interaction) in a meta-analysis. Cardiovascular mortality was lower for more vs less intensive therapy (3.48% vs 4.07%; RR, 0.84 [95% CI, 0.79 to 0.89]) but varied by baseline LDL-C level. Meta-regression showed more intensive LDL-C lowering was associated with a greater reduction in cardiovascular mortality with higher baseline LDL-C levels (change in RRs per 40-mg/dL increase in baseline LDL-C, 0.86 [95% CI, 0.80 to 0.94]; P < .001; ARD, -1.0 incident cases per 1000 person-years [95% CI, -1.51 to -0.45]), but only when baseline LDL-C levels were 100 mg/dL or greater (P < .001 for interaction) in a meta-analysis. Trials with baseline LDL-C levels of 160 mg/dL or greater had the greatest reduction in all-cause mortality (RR, 0.72 [95% CI, 0.62 to 0.84]; P < .001; 4.3 fewer deaths per 1000 person-years) in a meta-analysis. More intensive LDL-C lowering was also associated with progressively greater risk reductions with higher baseline LDL-C level for myocardial infarction, revascularization, and MACE.
CONCLUSIONS AND RELEVANCE: In these meta-analyses and meta-regressions, more intensive compared with less intensive LDL-C lowering was associated with a greater reduction in risk of total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels. This association was not present when baseline LDL-C level was less than 100 mg/dL, suggesting that the greatest benefit from LDL-C-lowering therapy may occur for patients with higher baseline LDL-C levels.
参考来源
- Navarese EP, Robinson JG, Kowalewski M, et al. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. JAMA. 2018. PMID: 29677301. doi:10.1001/jama.2018.2525
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。